Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 1,301–1,400 of 1,619
Pathophysiological functions of self-derived DNA
Ori, D., & Kawai, T. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2070616 · Cited by 1
Endothelial cell dysfunction and senescence: biologic mechanisms and hemodynamic consequences
Suda, M., Shimizu, I., Yoshida, Y., Katsuumi, G., & Minamino, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91391-1.00023-6 · Cited by 3
Lautrup, S., Anisimov, A. S., Lagartos-Donate, M. J., & Fang, E. F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91617-2.00010-9 · Cited by 4
Selected phenolic compounds in the modulation of biochemical pathways involved in aging
Spagnuolo, L., Lelli, D., Lattanzi, G., Dugo, L., Pedone, C., & Gara, L. D. (2023) · Redox Experimental Medicine · doi:10.1530/rem-23-0017 · Cited by 2
Victorelli, S. G., & Passos, J. F. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01276-9 · Cited by 1
Self-citationGetting the Timing Right: Controlling BCL-2 Inhibition as an Antifibrotic Therapy
Cooley, J. C., & Redente, E. F. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0436ed · Cited by 2
Palmer, A. K., & Kirkland, J. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00012-8 · Cited by 2
Self-citationKulkarni, T., Newton, C. A., Gupta, S., Samara, K. D., & Bernstein, E. J. (2024) · Pulmonary Therapy · doi:10.1007/s41030-024-00267-x · Cited by 1
Yoshino, H., Tadano, K., Omiya, C., Ishii, K., & Munakata, N. (2024) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncae089 · Cited by 1
En búsqueda de nuevos tratamientos para la fibrosis pulmonar idiopática
Maldonado, M. (2024) · Entretextos (en línea, León, Gto.)/Entretextos · doi:10.59057/iberoleon.20075316.202440746
The Role of Methyltransferase SETD7 in Stress-Response of Normal Human Stromal Cells
Konyushatova, А. О., Deryabin, P. I., Shatrova, A. N., & Borodkina, A. V. (2025) · Cell and Tissue Biology · doi:10.1134/s1990519x25010080 · Cited by 1
Liao, Y., & Wu, B. (2025) · Biomedical Reports · doi:10.3892/br.2025.1936 · Cited by 2
Tsubouchi, K., Yanagihara, T., Kiyomi, F., Yamamoto, Y., Arimura‐Omori, M., Hamada, N., Ichiki, K., Takata, S., Ishii, H., Kitasato, Y., et al. (2025) · Respirology · doi:10.1111/resp.70120 · Cited by 1
Outsourcing Invasion, a Novel Function for Extracellular Vesicles in the Lung
Shentu, T., & Hagood, J. S. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0345ed · Cited by 1
Transplantation From Older Donors: Can Senolytics Turn Back the Clock?
Dixon, W., Feng, S., & Gardner, J. M. (2021) · Transplantation · doi:10.1097/tp.0000000000003538 · Cited by 1
Questions of ethical regulation of immunobiological therapy of some occupational lung diseases
Shpagina, L. A., Паначева, Л. А., & Золотухина, Е. В. (2021) · Perm Medical Journal · doi:10.17816/pmj383131-140 · Cited by 1
An Experimental Model to Induce Homogeneous and Progressive Pulmonary Fibrosis in Rats
Abdullah, S. M., & Mazumder, P. M. (2021) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.55.3s.182 · Cited by 1
Lung aging and senescence in health and disease
Hernández‐González, F., Saito, N., Agustí, A. G. N., Sellarés, J., & Faner, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00002-x · Cited by 2
Analysis of the Potential Relationship between Aging and Pulmonary Fibrosis Based on Transcriptome
Fu, S., Tang, X., Xu, Y., Song, X., Qian, X., Hu, Y., & Zhang, M. (2022) · Life · doi:10.3390/life12121961 · Cited by 2
Popper, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-55743-0_8 · Cited by 1
Redox regulation in pulmonary fibrosis: towards therapeutic targets
Veith (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190524cv · Cited by 1
Pharmacological inhibition of longevity regulator PAPP-A restrains mesenchymal stromal cell activityPreprint
Mohrin, M., Liu, J., Zavala‐Solorio, J., Bhargava, S., Trumble, J. M., Brito, A., Hu, D. Z., Brooks, D. J., Bouxsein, M., Baron, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.05.936310 · Cited by 1
Tanner, L., Bergwik, J., Bhongir, R. K. V., & Egesten, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.01.470755 · Cited by 1
Zhou, Y., Ewing, R. M., Davies, D. E., Wang, Y., & Jones, M. G. (2022) · medRxiv · doi:10.1101/2022.01.11.22269085 · Cited by 2
IL-11 system participates in pulmonary artery remodeling and hypertension in pulmonary fibrosisPreprint
Milara, J., Roger, I., Montero, P., Artigues, E., Escrivá, J., & Cortijo, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2022877/v1 · Cited by 1
Fuentes-Flores, A., Gerónimo‐Olvera, C., Ñecuñir, D., Patel, S. K., Bons, J., Wright, M. C., Geschwind, D. H., Höke, A., Gomez-Sanchez, J. A., Schilling, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.07.519441 · Cited by 1
The human pathome shows sex specific aging patterns post-developmentPreprint
Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Heckenbach, I., Petr, M. A., Bakula, D., Mortensen, L. H., & Scheibye‐Knudsen, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.27.530179 · Cited by 3
Uhl, K. L., Paithankar, S., Leshchiner, D. R., Jager, T. E., Abdelgied, M., Tripp, K., Peraino, A. M., Kakazu, M. T., Lawson, C. K., Chesla, D. W., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.01.530431 · Cited by 1
The human pathome shows sex and tissue specific aging patternsPreprint
Scheibye‐Knudsen, M., Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Heckenbach, I., Petr, M. A., Bakula, D., & Mortensen, L. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2652110/v1 · Cited by 1
Lérida‐Viso, A. (2023) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/194709 · Cited by 1
Amniotic Fluid Organoids As Personalized Tools For Real-Time Modeling Of The Developing FetusPreprint
Babošová, O., Weisz, B., Rabinowitz, G., Avnet, H., Shani, H., Schwartz, A., Batsry, L., Pardo, N., Miller, T. E., Stockheim, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.05.561078 · Cited by 1
Gerontogen as the Toxicology of AgingPreprint
Rahma, R., & Barinda, A. J. (2024) · Preprints.org · doi:10.20944/preprints202404.0659.v1 · Cited by 1
Babaei‐Jadidi, R., Clements, D., Wu, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.03.592025 · Cited by 1
Single-cell-based evidence for GLS1 inhibitor as a bona fide senolytic agent in vivoPreprint
Okamura, Y. T., Wang, T.-W., Kawakami, S., Morimura, T., Johmura, Y., & Nakanishi, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.22.666220 · Cited by 1
Cherqui, U., Sopher, I., Akiva, H., Menahem, O., Kopitman, E., Blecher‐Gonen, R., Keren‐Shaul, H., Rachmian, N., Mayo, A., Alon, U., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.14.688272 · Cited by 1
Mejías, J. C., Krishnan, K., Ruta, A., Ramanujam, A. S., Gray-Gaillard, E. F., Huyer, L. D., Maestas, D. R., Nagaraj, S., Yu, F. H., Rindone, A. N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.05.697727 · Cited by 3
Anerillas, C., Altés, G., Grešová, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.05.703986 · Cited by 1
Vázquez-Villaseñor, I. (2018) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Kwiatkowska, S. (2018) · Advances in respiratory medicine · doi:10.5603/arm.58535
Future Directions for IPF Research
Craig, J. M., Aggarwal, N. R., & Kiley, J. P. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_20
Ablation of Arf -expressing cells ameliorates cigarette smoke-induced lung dysfunction in micePreprint
Mikawa, R., Sato, T., Suzuki, Y., Baskoro, H., & Sugimoto, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/809160
Targeting the Ubiquitin Proteasome System in Pulmonary Fibrosis
Thorley, A. J., Krautwald, S., & Rowlands, D. J. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00165
The Role of the Innate Immune System in Interstitial Lung Disease
Hogaboam, C. M., Hohmann, M. S., & Espíndola, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11575-2
Discovery of Senolytics and the Pathway to Early Phase Clinical Trials
Gerdes, E. O. W., Zhu, Y. Z., Tchkonia, T., & Kirkland, J. L. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_2
Self-citationMorphological and functional studies in a sheep model of pulmonary fibrosis
Dewage, V., & Nimanthi, S. (2020) · Minerva Access (University of Melbourne)
Roque, W., Cuevas-Mora, K., Sales, D., Li, W. V., Rosas, I. O., & Romero, F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.08.084459
Senotherapeutics: Experimental therapy of cellular senescence
Justice, J. N., Niedernhofer, L. J., & Orr, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-815962-0.00012-3
Rahman, I., Kaur, G., & Sundar, I. K. (2021) · Research Square · doi:10.21203/rs.3.rs-140689/v1
Idelevich, P., & Reed, K. M. (2021) · Research Square · doi:10.21203/rs.3.rs-203231/v1
Zheng, Y. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3428
Prevention and Treatment of the Troubles of the Elderly
Libertini, G., Corbi, G., Conti, V., Shubernetskaya, O. S., & Ferrara, N. (2021) · Advances in studies of aging and health · doi:10.1007/978-3-030-73774-0_8
TERT-dependent senescence and inflammation in ageing, using zebrafish as a model
Martins, R. R. (2020) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Zheng, P., Sun, S., Wang, J., Cheng, Z. J., Lei, K. C., Xue, M., Zhang, T., Huang, H., Zhang, X. D., & Sun, B. (2021) · Research Square · doi:10.21203/rs.3.rs-729282/v1
Novel probes, carriers and prodrugs to target senescent cells in vivo
Lozano‐Torres, B. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/172175
Targeting Molecular and Cellular Mechanisms in Idiopathic Pulmonary Fibrosis
Banudevi, S., & Bose, V. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_12
DEVELOPMENT OF A NOVEL METABOLIC GLYCO-SENSING APPROACH WITH ANTI-AGING POTENTIAL
AlSadek, D. M. M., Badr, H. A., & Ahmed, H. (2018) · Mansoura Veterinary Medical Journal · doi:10.21608/mvmj.2018.198486
Huard, J. (2021) · Orthopedics and Rheumatology Open Access Journal · doi:10.19080/oroaj.2021.17.555971
Interaction Between Epithelial and Mesenchymal Cells in Interstitial Lung Disease
Cohen, M., & Wolters, P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11657-5
Sandbo, N. K. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_7
A geroscience approach for osteosarcopenia: Autophagy and senescence as therapeutic targets
Cordero, N. P., Schoenlein, P. V., Fulzele, S., & Hill, W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820088-9.00031-7 · Cited by 1
Cellular senescence and other aging mechanisms in bone and muscle
Kaur, J., & Farr, J. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820088-9.00008-1
Effects of anti-fibrotic standard of care drugs on senescent human lung fibroblastsPreprint
Garcia, S. B., Hohmann, M. S., Coelho, A. L., Verri, W. A., Jr., & Hogaboam, C. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.06.490939
Schumacher, B. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734825206.793563347
Faculty Opinions recommendation of Fisetin is a senotherapeutic that extends health and lifespan.
Schumacher, B. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734139615.793563345
Gold, M. R. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734674689.793558446
Mason, R. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733607913.793560955
Translational research in the fastest-growing population: older adults
Justice, J. N., High, K. P., & Kritchevsky, S. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00032-5
She, J., & Wang, C.-Y. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733607913.793549270
Pawelec, G. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734674689.793557283
Idiopathic Pulmonary Fibrosis: Let’s Keep the Focus on the A(ge)TII cell
Lehmann, M., & Rojas, M. M. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202204-0703ed
Wu, Y., Zhu, B., Zhang, R., Goplen, N. P., Gao, X., Narasimhan, H., Shi, A., Chen, Y. M., Li, Y., Dong, H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.04.494822
Müller, H. R., Schroeder, H. T., Miragem, A. A., & de Bittencourt, P. I. H. (2022) · Research Square · doi:10.21203/rs.3.rs-1714008/v1
The possible biomarkers of the «postСovid-19 syndrome» in patients with type 2 diabetes
Jburi, L. R., & Kopylova, M. V. (2022) · ТЕНДЕНЦИИ РАЗВИТИЯ НАУКИ И ОБРАЗОВАНИЯ · doi:10.18411/trnio-04-2022-88
Quiescencia y senescencia: enfoque traslacional al paciente oncológico y críticamente enfermo.
Moscoso, S. X. A., Montalvo-Villagómez, M., González, F. E. J., Páez, P. A. V., Montero, C. G. V., & Vélez-Páez, J. L. (2019) · Revista Ecuatoriana de Ciencia Tecnología e Innovación en Salud Pública · doi:10.31790/inspilip.v4i1.154 · Cited by 1
Jia, M., Rosas, L., Kapetanaki, M. G., Tabib, T., Sebrat, J., Cruz, T., Bondonese, A., Mora, A. L., Lafyatis, R., Rojas, M. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.29.501956
Impairing Senohemostasis by Ablating DPP4 Improves AtherosclerosisPreprint
Herman, A. B., Tsitsipatis, D., Anerillas, C., Mazan-Mamczarz, K., Carr, A. E., Gregg, J. M., Wang, M., Zhang, J., Michel, M., Harris, S. C., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4186256
Interventions that target fundamental aging mechanisms: myths and realities
Gerdes, E. O. W., Zhu, Y. Z., Tchkonia, T., & Kirkland, J. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823761-8.00009-4
Self-citationXu, Q., Zhang, M., Tang, M., Li, Z., Liu, Y., Rao, Z., Yang, K., He, X., Ma, R., & Xue, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2092293/v1
Küçükgüven, A., & Vargel, İ. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98804-9.00032-3
Nosrati, F., Grillari, J., Azarnia, M., Nabiuni, M., Moghadasali, R., Karimzadeh, L., & Lämmermann, I. (2022) · Research Square · doi:10.21203/rs.3.rs-2134837/v1
Nawroth, P. P., Kumar, V., & Kopf, S. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1902-4778
Ma, H., Wu, X., Li, Y., & Xia, Y. (2022) · Kompass Neumología · doi:10.1159/000526906
Preclinical evaluation of senescence-based strategies to improve cancer therapy
Estepa‐Fernández, A. (2022) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/188845
Xu, Q., Zhang, M., Tang, M., Li, Z., Liu, Y., ma, T., Rao, Z., Yang, K., He, X., Ma, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2245802/v1
Pulmonary Fibrosis: One Manifestation, Various Diseases
Ruaro, B., Matucci‐Cerinic, M., Baratella, E., Confalonieri, M., Salton, F., & Hughes, M. (2022) · Frontiers research topics · doi:10.3389/978-2-83250-654-7
Idiopathic pulmonary fibrosis - novel approach on future treatment
PACEK, K., Piekarska, M., Pikulicka, A., Jedlina, K., SZULC, I., Kasperski, R., SWACHA, W., & Makowska, K. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.02.039
Massoud, G. P., Eid, A. E., Booz, G. W., Rached, L., Yabluchanskiy, A., & Zouein, F. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823679-6.00009-6 · Cited by 1
Influence of miR-142-3p on Pulmonary Fibrosis Through Regulation of p53/NF-κB
Shen, Y., Li, H.-J., Zhang, K., Li, S.-Q., & Xu, Y. (2023) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x231175222
LungElast—an open-source, flexible, low-cost, microprocessor-controlled mouse lung elastometer
Roberts, J. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-38310-7
Zhan, Y., Gu, Y., Yang, R., Deng, Z., Chen, S., Huang, Q., Wu, J., Chen, J., & Xie, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3304066/v1
Editorial: Reviews in pulmonary medicine 2022
Wang, S., & Baldi, B. G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1296581
Adenine Nucleotide Translocases and Cellular Senescence in Idiopathic Pulmonary Fibrosis
Kobayashi, T., Fujimoto, H., D’Alessandro‐Gabazza, C. N., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0386le
Macrolides and Interstitial Lung Diseases
Hara, Y., & Kaneko, T. (2024) · Progress in inflammation research · doi:10.1007/978-3-031-42859-3_8
Xu, P., Wang, M., Song, W., Wang, Q., Yuan, G., Sudmant, P. H., Zare, H., Tu, Z., Orr, M. E., & Zhang, B. (2022) · Figshare · doi:10.6084/m9.figshare.18094452
Ma, Y., Yi, C., Cai, N., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4207895/v1
Aging shapes infection profiles of influenza A virus and SARS-CoV-2 in human lung slicesPreprint
Brügger, M., Machahua, C., Zumkehr, B., Cismaru, C. V., Jandrasits, D., Dorn, P., Marti, T. M., Zimmer, G., Thiel, V., Funke-Chambour, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.14.589423
Modern Approaches to the Creation of 2D and 3D Cellular Models for the Study of Lung Fibrosis
Tolstoluzhinskaya, A., Basalova, N. A., & Efimenko, A. Y. (2024) · Cell and Tissue Biology · doi:10.1134/s1990519x26070023
Kousathanas, A., Odhams, C. A., Cook, J. P., Hu, Y., Klee, S., Erzurumluoglu, A. M., Ramírez, F., Mayr, C. H., Schäfer, D., Beck, L., et al. (2024) · medRxiv · doi:10.1101/2024.08.16.24312138
Reversing Immunosenescence with Senolytics to Enhance Tumor ImmunotherapyPreprint
Liu, N., Wu, J., Deng, E., Zhong, J., Wei, B. K., Cai, T., Duan, X., Fu, S., Osei-Hwedieh, D. O., Sha, O., et al. (2024) · medRxiv · doi:10.1101/2024.10.14.24315428
Self-citation
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.